A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Key facts
- Where
- Amsterdam, Maastricht, and Rotterdam, NetherlandsSee the 3 sites
- Phase
- Phase 3
Where in Netherlands
- Amsterdam UMC, locatie AMCAmsterdam, NetherlandsContact: Kardigan Clinical Trial TeamNot yet recruiting
- Maastricht University Medical CenterMaastricht, NetherlandsContact: Kardigan Clinical Trial TeamNot yet recruiting
- Erasmus MCRotterdam, NetherlandsContact: Kardigan Clinical Trial TeamNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Kardigan, Inc.
- Trial code
- NCT07771465
- Record updated
- 4 November 2026
- Original description
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.Read full original descriptionShow less
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Danicamtiv is an investigational medication, which means it is still being studied and has not been approved. The purpose of this study is to learn how well danicamtiv works, how safe it is, how well people can take it when used in patients with genetic or familial dilated cardiomyopathy (DCM). There are currently no approved medicines made specifically to treat genetic or familial DCM.
Inclusion: Completed 24 weeks of blinded study treatment (corresponding to the Week 26 Visit in DAN-301) and planned assessments in Part 1 or Part 2 of the DAN-301 study; If sexually active, must use a highly effective birth control method from the Screening Visit through 3 months after the last dose; Is able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to local and institutional guidelines before the first study-specific procedure.
Exclusion: Acute coronary syndrome or hemodynamically significant epicardial coronary disease, or coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) performed within 90 days of DAN-302 Screening Visit; Recent (<90 days) hospitalization for heart failure (HF) or use of IV diuretic; Hospitalization for sepsis or other systemic infections within 30 days of Screening. A systemic infection includes suspected or confirmed infection associated with fever, hemodynamic instability, bacteremia, or organ dysfunction typically requires urgent evaluation and/or acute care; Any malignancy requiring treatment after enrollment in DAN-301 that could limit patient's survival; Other recent (<90 days) cardiovascular events (e.g., cerebrovascular accident).